— Published date: 6/2/2026
Value proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Desc…
— Published date: 5/30/2026
Value Proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Descr…
— Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy.…
— Published Date: 5/14/2025
Value Proposition: Robust and reliable biomarker to accurately predict patient response to PARP inhibitors and platinum chemotherapy for high grade serous ovarian cancer.
Technology Description
Researchers at Washington University in St. Louis have developed an automat…
— Published Date: 5/14/2025
Value proposition: Self-sustaining chimeric macrophages as a novel approach to target amyloid plaques resulting in improved efficacy and survival in patients.
Technology Description
Researchers from Washington University in St. Louis have engineered macrophages to expre…
| Name | # Summaries | Author | Action |
|---|---|---|---|
| 15 | |||
| 13 | |||
| 1 | |||
| 15 | |||
| 26 | |||
| 14 | |||
| 14 |
Creating...
